{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:56:24Z","timestamp":1784249784946,"version":"3.55.0"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009009","name":"Novartis Pharmaceuticals Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0210417","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T18:32:26Z","timestamp":1547490746000},"page":"e0210417","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies"],"prefix":"10.1371","volume":"14","author":[{"given":"Pierre","family":"Duquette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5280-1526","authenticated-orcid":true,"given":"Souka\u00efna","family":"Mouallif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Nakhaipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7229-121X","authenticated-orcid":true,"given":"Robyn","family":"Schecter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"key":"ref1","unstructured":"MSIF. Atlas of MS 2013. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.msif.org\/wp-content\/uploads\/2014\/09\/Atlas-of-MS.pdf\" xlink:type=\"simple\">https:\/\/www.msif.org\/wp-content\/uploads\/2014\/09\/Atlas-of-MS.pdf<\/ext-link>."},{"key":"ref2","unstructured":"Multiple sclerosis society of Canada. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/mssociety.ca\/about-ms\" xlink:type=\"simple\">https:\/\/mssociety.ca\/about-ms<\/ext-link>."},{"key":"ref3","first-page":"101","article-title":"Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents","volume":"5","author":"N Girouard","year":"2011","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1017\/cjn.2018.17","article-title":"Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing","volume":"45","author":"MS Freedman","year":"2018","journal-title":"The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"i3518","DOI":"10.1136\/bmj.i3518","article-title":"Disease modifying therapies for relasing multiple sclerosis","volume":"354","author":"DM Wingerchuk","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"JA Cramer","year":"2008","journal-title":"Value Health"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3111\/13696998.2011.618517","article-title":"The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate","volume":"14","author":"MA Oleen-Burkey","year":"2011","journal-title":"J Med Econ"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11533330-000000000-00000","article-title":"Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study","volume":"30","author":"SC Steinberg","year":"2010","journal-title":"Clin Drug Investig"},{"issue":"9","key":"ref9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3111\/13696998.2015.1044276","article-title":"Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis","volume":"18","author":"S Yermakov","year":"2015","journal-title":"J Med Econ"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","article-title":"Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis","volume":"28","author":"H Tan","year":"2011","journal-title":"Adv Ther"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1468-1331.2010.03110.x","article-title":"The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis","volume":"18","author":"V Devonshire","year":"2011","journal-title":"Eur J Neurol"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00415-009-0096-y","article-title":"Factors that influence adherence with disease-modifying therapy in MS","volume":"256","author":"K Treadaway","year":"2009","journal-title":"J Neurol"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00023210-200923060-00001","article-title":"Improving compliance with interferon-beta therapy in patients with multiple sclerosis","volume":"23","author":"E Portaccio","year":"2009","journal-title":"CNS Drugs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1471-2377-13-138","article-title":"Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study","volume":"13","author":"N Agashivala","year":"2013","journal-title":"BMC Neurol"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3111\/13696998.2014.940422","article-title":"Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis","volume":"17","author":"N Bergvall","year":"2014","journal-title":"J Med Econ"},{"issue":"8","key":"ref16","first-page":"844","article-title":"Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year","volume":"23","author":"KM Johnson","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7224\/1537-2073.2011-038","article-title":"Facilitating medication adherence in patients with multiple sclerosis","volume":"15","author":"G Remington","year":"2013","journal-title":"Int J MS Care"},{"key":"ref18","unstructured":"IMS RX dynamics. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.imsbrogancapabilities.com\/en\/market-insights\/rx-dynamics.html\" xlink:type=\"simple\">http:\/\/www.imsbrogancapabilities.com\/en\/market-insights\/rx-dynamics.html<\/ext-link>."},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","article-title":"The assessment of refill compliance using pharmacy records: methods, validity, and applications","volume":"50","author":"JF Steiner","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(11)70099-0","article-title":"Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study","volume":"10","author":"B Khatri","year":"2011","journal-title":"Lancet Neurol"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"L Kappos","year":"2010","journal-title":"N Engl J Med"},{"issue":"1 Suppl A","key":"ref22","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.18553\/jmcp.2013.19.s1.S24","article-title":"Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis","volume":"19","author":"J Menzin","year":"2013","journal-title":"J Manag Care Pharm"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0210417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T06:15:42Z","timestamp":1662790542000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0210417"}},"subtitle":[],"editor":[{"given":"Sreeram V.","family":"Ramagopalan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0210417","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]}}}